Person: COŞKUN, NEJDET
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
COŞKUN
First Name
NEJDET
Name
10 results
Search Results
Now showing 1 - 10 of 10
Publication Malignancy risk in systemic lupus erythematosus patients treated with cyclophosphamide(Clinical & Exper Rheumatology, 2015-05-01) Yilmaz, N.; Emmungil, H.; Gücenmez, S.; Özen, G.; Yıldız, F.; Balkarlı, A.; Kimyon, G.; Coşkun, B. Necdet; Doğan, I.; Pamuk, O. N.; Yaşar, S.; Cetin, G. Yildirim; Yazıcı, A.; Esmen, S. Ergülü; Cağatay, Y.; Yılmaz, S.; Celle, A.; Cefle, A.; Sayarhoğlu, M.; Kaşifoğlu, T.; Karadağ, O.; Pehlivan, Yavuz; Dalkılıç, Ediz; Kısacık, B.; Cobankara, V.; Erken, E.; Direskeneli, H.; Aksu, K.; Yavuz, S.; COŞKUN, NEJDET; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; Romatoloji Bölümü; 0000-0003-0298-4157; ETE-5180-2022; AAG-8227-2021; AAG-7155-2021Publication Covid-19 vaccination of spondyloarthritis patients receiving biological therapy: Real-life data(BMJ Publishing Group, 2022-06-01) Yıldırım, T. Demirci; Akleylek, C.; Cinakli, H.; Yildirim, D.; Hakbilen, S.; Coşkun, B. N.; Okyar, B.; Işık, O. Ozdemir; Sağir, R. Piskin; Apaydin, H.; Gülle, S.; Erez, Y.; İnel, T. Yuce; Yilmaz, N.; Akar, S.; Tufan, A.; Yılmaz, S.; Pehlivan, Yavuz; Cetin, G. Yildirim; Cefle, A.; Koca, S. S.; Erten, S.; Yazici, A.; Dalkılıç, Ediz; Can, G.; Sari, I.; Birlik, M.; Önen, F.; COŞKUN, NEJDET; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; Ramatoloji Bölümü; JHC-5173-2023; FQP-0451-2022; AAG-7155-2021Publication Factors associated with hip involvement and its impact on treatment decision in patients with axial spondyloarthritis; Treasure experience(BMJ Publishing Group, 2022-06-01) Ediboğlu, E. Durak; Kalyoncu, U.; Solmaz, D.; Kaşifoğlu, T.; Tekgöz, E.; Beş, C.; Erden, A.; Yağız, B.; Kanitez, N. A.; Ertenli, A. I.; Coşkun, B. N.; Mercan, R.; Kiraz, S.; Yazısız, V.; Küçükşahin, O.; Ateş, A.; Yılmaz, R.; Pehlivan, Y.; Emmungil, H.; Bilge, N. S. Yasar; Kimyon, G.; Ersözlü, E. D.; Dalkılıç, E.; Koca, S. S.; Akar, S.; COŞKUN, NEJDET; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Tıp Fakültesi; Dahili Tıp Bölümü; Romatoloji Bölümü; JHC-5173-2023; FQP-0451-2022; AAG-7155-2021Publication Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life treasure prospective data(Clinical & Exper Rheumatology, 2021-07-01) Kimyon, G.; Kalyoncu, U.; Kiraz, S.; Bes, C.; Coskun, N.; Yagiz, B.; Kucuksahin, O.; Kanitez, N.; Erden, A.; Kilic, L.; Bilging, E.; Kasifoglu, T.; Emmungil, H.; Koca, S. S.; Akar, S.; Cinar, M.; Yazisiz, V; Ates, A.; Ersozlu, D.; Gonulle, E.; Mercan, R.; Ertenli, I; Coskun, N.; COŞKUN, NEJDET; Tıp FakültesiObjectiveTo determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA).MethodsThe TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019,2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test).ResultsOf 2556 RA patients 1526 (59.7%) were receiving concomitant LEE (n=646, 42 3%; median follow up 35 months) or concomitant MTX (n=880, 573%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEE group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEE group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEE + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti-TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups.ConclusionLEE in combination with either anti TNF or non anti DIF drugs appears as an effective and safe therapeutic option at least as MIX.Publication Paradoxical reactions, especially psoriasis in rheumatology patients receiving biologic therapy from the treasure database: A 5-year follow-up study(BMJ Publishing Group, 2022-06-01) Yağız, Burcu; Lermi, Nihal; Coşkun, B. Nejdet; Dalkılıç, Ediz Hüseyin; Kiraz, S.; Ertenli, A. I.; Bilgin, E.; Yılmaz, R.; Ateş, A.; Tufan, A.; Mercan, R.; Cinakli, H.; Akar, S.; Kaşifoğlu, T.; Türk, S. M.; Gönüllü, E.; Erden, A.; Beş, C.; Emmungil, H.; Kalyoncu, U.; Pehlivan, Y.; TReasure; YAĞIZ, BURCU; LERMİ, NİHAL; COŞKUN, NEJDET; DALKILIÇ, HÜSEYİN EDİZ; 0000-0003-0298-4157; JHC-5173-2023; FGB-0552-2022; AAG-7155-2021; JQW-5031-2023Publication Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: Efficacy and safety analysis from treasure real-life data(Bmj Publishing Group, 2021-06-01) Kalyoncu, U.; Bilgin, E.; Erden, A.; Satis, H.; Tufan, A.; Tekgoz, E.; Ates, A.; Kucuksahin, O.; Yazisiz, V.; Kimyon, G.; Bes, C.; Ertenli, A. I.; Kiraz, S.; Coskun, B. N.; COŞKUN, NEJDET; Yagiz, B.; YAĞIZ, BURCU; Tıp Fakültesi; Romatoloji Ana Bilim Dalı; 0000-0003-0298-4157; 0000-0002-0866-1503; JQW-5031-2023; AAG-7155-2021Publication Epidemiological characteristics of viral hepatitis in patients with rheumatic diseases - implications from treasure database(BMJ Publishing Group, 2022-06-01) Ersözlü, D.; Ekici, M.; Coşkun, B. Nejdet; Badak, S. O.; Bilgin, E.; Kalyoncu, U.; Yağız, Burcu; Pehlivan, Yavuz; Küçükşahin, O.; Erden, A.; Solmaz, D.; Atagündüz, P.; Kimyon, G.; Beş, C.; Çolak, S.; Mercan, R.; Kaşifoğlu, T.; Emmungil, H.; Kanitez, N. A.; Ateş, A.; Koca, S. S.; Kiraz, S.; Ertenli, A. I.; COŞKUN, NEJDET; YAĞIZ, BURCU; PEHLİVAN, YAVUZ; Tıp Fakültesi; Romatoloji Bölümü; FQP-0451-2022; AAG-7155-2021; JQW-5031-2023Publication Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data(Clinical & Exper Rheumatology, 2022-11-01) Kalyoncu, U.; Bilgin, E.; Erden, A.; Satış, H.; Tufan, A.; Tekgöz, E.; Ateş, A.; Coşkun, B. N.; Yağız, B.; Kucuksahin, O.; Yazısızz, V.; Kimyon, G.; Bes, C.; Başıbüyük, C. S.; Alkan, S.; Cesur, T. Y.; Ertenli, I.; Kiraz, S.; COŞKUN, NEJDET; YAĞIZ, BURCU; Tıp Fakültesi; AAG-7155-2021; JQW-5031-2023Objective Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is a major concern in RA. These patients have been included in clinical trials and in the post-marketing setting of RA patients using tofacitinib. We aimed to assess the real-life efficacy and safety of tofacitinib in patients with RA-ILD.Methods RA patients with ILD diagnosis based on the HRCT images of the lungs from eight different centres recruited to study. As a control group, RA patients without ILD under tofacitinib were included. Demographic data, patients' characteristics, available pulmonary function tests regarding RA and RA-ILD at the visit in which tofacitinib was initiated and for the last follow-up visit under tofacitinib were recorded. Reasons for tofacitinib discontinuation were also recorded. Drug retention rates were compared by log-rank test. p-value <0.05 was considered statistically significant.Results A total of 47(42.6% male) RA patients with RA-ILD and a control group of 387 (17.8% male) patients without RA-ILD were included in analysis. After the median of 12 (9-19) months follow-up, mean FEV1%; 82.1 vs. 82.8 (pre/post-treatment, respectively, p=0.08), mean FVC%; 79.8 vs. 82.8 (pre/post-treatment, respectively, p=0.014) were stable and worsening was observed in 2/18 (11.1%) patients. Retention rates were similar (p=0.21, log-rank). In RA-ILD group, the most common cause of drug discontinuation was infections (6.3 vs. 2.4 per 100 patient-years).Conclusion Treatment strategy of RA-ILD patients is still based on small observational studies. A high rate of discontinuation due to infections was observed in RA-ILD patients under tofacitinib; however, RA-ILD patients were older than RA patients without ILD.Publication The differences between the first preferred biological dmard and the drug survival in geriatric and younger adult population with rheumatoid arthritis and psoriatic arthritis: Treasure real-life data(BMJ Publishing Group, 2022-06-01) Gönüllü, E.; Kalyoncu, U.; Yağız, Burcu; Ateş, A.; Küçükşahin, O.; Bilge, S. Yaşar; Kanitez, N. A.; Çınar, M.; Ersözlü, D.; Mercan, R.; Akar, S.; Kaşifoğlu, T.; Coşkun, B. Nejdet; Koca, S. S.; Bilgin, E.; Yazısız, V.; Dalkılıç, Ediz; Yılmaz, R.; Kimyon, G.; Türk, S. M.; Erden, A.; Beş, C.; Emmungil, H.; Pehlivan, Yavuz; Ertenli, A. I.; Kiraz, S.; TReasure; YAĞIZ, BURCU; COŞKUN, NEJDET; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Tıp Fakültesi; Romatoloji Bölümü; FQP-0451-2022; JHC-5173-2023; AAG-7155-2021; JQW-5031-2023Publication Do peripheral and extra musculoskeletal manifestations have an impact on biologic dmard prescribing patterns in axial spondyloarthritis: The results of treasure experience(Bmj Publishing Group, 2021-06-01) Ediboglu, E. Durak; Solmaz, D.; Karadag, O.; Cinar, M.; Ertenli, A. I.; Ersozlu, D.; Kucuksahin, O.; Ates, A.; Kiraz, S.; Tekgoz, E.; Emmungil, H.; Gonullu, E.; Kabadayi, G.; Kasifoglu, T.; Mercan, R.; Kimyon, G.; Colak, S.; Bes, C.; Bilge, N. S. Yasar; Yazisiz, V.; Koca, S. S.; Atagunduz, P.; Kanitez, N. A.; Kalyoncu, U.; Akar, S.; Pehlivan, Y.; Coskun, B. N.; COŞKUN, NEJDET; Yagiz, B.; YAĞIZ, BURCU; Fen Edebiyat Fakültesi; Kimya Bölümü; 0000-0002-9035-689X; 0000-0003-1372-1555; 0000-0002-0866-1503; 0000-0001-5184-4404; 0000-0002-6990-4206; 0000-0003-2076-3403; 0000-0003-1185-5816; 0000-0002-3734-1242; HJY-2666-2023; JQW-5031-2023; HJI-6996-2023; AAG-7155-2021; GZA-3287-2022; B-1448-2016; AFO-6929-2022; AAZ-5845-2021; AAD-5448-2019; AAK-7851-2021; W-7332-2019